Lisa Rojkjaer, M.D., is the Executive Vice President and Chief Medical Officer at Rigel Pharmaceuticals Inc., a biotechnology company focused on developing novel therapies for hematologic disorders, cancer, and rare diseases. Dr. Rojkjaer brings extensive experience in clinical development, medical affairs, and drug safety to her role at Rigel. She earned her medical degree from the University of Copenhagen and has held leadership positions at several prominent pharmaceutical companies, including Genentech, where she served as Senior Vice President of Product Development. Throughout her career, Dr. Rojkjaer has been instrumental in advancing the development of numerous successful therapies across various therapeutic areas. Her expertise in hematology and oncology has been particularly valuable in guiding Rigel's clinical programs, including the development of TAVALISSE® (fostamatinib disodium hexahydrate), the company's first FDA-approved product for the treatment of chronic immune thrombocytopenia. Under her leadership, Rigel has expanded its pipeline to include promising candidates for other hematologic disorders and rare diseases, positioning the company for continued growth and success. As Chief Medical Officer at Rigel, Dr. Rojkjaer oversees the company's clinical development, medical affairs, and pharmacovigilance functions. She plays a critical role in shaping the company's strategic direction and ensuring that Rigel's therapies meet the highest standards of safety and efficacy. Her dedication to advancing innovative treatments and improving patient outcomes has made her an invaluable asset to Rigel and the broader medical community.